
<html lang="en"     class="pb-page"  data-request-id="15dd2ff7-2f51-433a-9be6-80150f473d0e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00576;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-15;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)" /></meta><meta name="dc.Creator" content="Jiayi  Shen" /></meta><meta name="dc.Creator" content="Tao  Zhang" /></meta><meta name="dc.Creator" content="Su-Jie  Zhu" /></meta><meta name="dc.Creator" content="Min  Sun" /></meta><meta name="dc.Creator" content="Linjiang  Tong" /></meta><meta name="dc.Creator" content="Mengzhen  Lai" /></meta><meta name="dc.Creator" content="Rong  Zhang" /></meta><meta name="dc.Creator" content="Wei  Xu" /></meta><meta name="dc.Creator" content="Ruibo  Wu" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Cai-Hong  Yun" /></meta><meta name="dc.Creator" content="Hua  Xie" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone der..." /></meta><meta name="Description" content="Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone der..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 12, 2019" /></meta><meta name="dc.Type" content="rapid-communication" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00576" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00576" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00576" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00576" /></link>
        
    
    

<title>Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00576" /></meta><meta property="og:title" content="Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0008.jpeg" /></meta><meta property="og:description" content="Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selective EGFRL858R/T790M/C797S inhibitors. A representative compound, 8r-B, exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being a significantly less potent for EGFRWT (IC50 &gt; 1.0 μM). Cocrystallographic structure determination and computational investigation were conducted to elucidate its target selectivity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00576"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00576">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00576&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00576&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00576&amp;href=/doi/10.1021/acs.jmedchem.9b00576" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 7302-7308</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00932" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Brief Article</span><a href="/doi/10.1021/jmv062i015_1302693" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR<sup>L858R/T790M/C797S</sup>)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jiayi Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiayi Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiayi++Shen">Jiayi Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tao Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Zhang">Tao Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Su-Jie Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Su-Jie Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao 266021, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Su-Jie++Zhu">Su-Jie Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Aosaikang Pharmacceutical Co. Ltd., No. 699 Kejian Road, Jiangsu Science Park, Nanjing 211112, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Sun">Min Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linjiang Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linjiang Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linjiang++Tong">Linjiang Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mengzhen Lai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengzhen Lai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengzhen++Lai">Mengzhen Lai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rong Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rong Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Zhang">Rong Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Xu">Wei Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ruibo Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ruibo Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ruibo++Wu">Ruibo Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cai-Hong Yun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cai-Hong Yun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><span class="conrtib-corresp"><strong>*</strong>C.-H.Y.: e-mail, <a href="/cdn-cgi/l/email-protection#f58c809b969db5979f9880db909180db969b"><span class="__cf_email__" data-cfemail="522b273c313a1230383f277c3736277c313c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cai-Hong++Yun">Cai-Hong Yun</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-8307" title="Orcid link">http://orcid.org/0000-0002-5880-8307</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hua Xie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hua Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>H.X.: e-mail, <a href="/cdn-cgi/l/email-protection#8ce4f4e5e9ccffe5e1e1a2edefa2efe2"><span class="__cf_email__" data-cfemail="b9d1c1d0dcf9cad0d4d497d8da97dad7">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Xie">Hua Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoyun Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyun Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>X.L.: e-mail, <a href="/cdn-cgi/l/email-protection#e488919c9dd6d4d5d2a48e8a91ca818091ca878a"><span class="__cf_email__" data-cfemail="d6baa3aeafe4e6e7e096bcb8a3f8b3b2a3f8b5b8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>K.D.: e-mail, <a href="/cdn-cgi/l/email-protection#6d0904030a06082d07031843080918430e03"><span class="__cf_email__" data-cfemail="aacec3c4cdc1cfeac0c4df84cfcedf84c9c4">[email protected]</span></a>; phone, +86 20 85223764.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00576&amp;href=/doi/10.1021%2Facs.jmedchem.9b00576" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 7302–7308</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 12, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 April 2019</li><li><span class="item_label"><b>Published</b> online</span>12 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 August 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00576" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00576</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7302%26pageCount%3D7%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJiayi%2BShen%252C%2BTao%2BZhang%252C%2BSu-Jie%2BZhu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D15%26contentID%3Dacs.jmedchem.9b00576%26title%3DStructure-Based%2BDesign%2Bof%2B5-Methylpyrimidopyridone%2BDerivatives%2Bas%2BNew%2BWild-Type%2BSparing%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTriple%2BMutant%2B%2528EGFRL858R%252FT790M%252FC797S%2529%26numPages%3D7%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7308%26publicationDate%3DAugust%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00576"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2882</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00576" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jiayi&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Su-Jie&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Linjiang&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Mengzhen&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Ruibo&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Cai-Hong&quot;,&quot;last_name&quot;:&quot;Yun&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7302-7308&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00576&quot;},&quot;abstract&quot;:&quot;Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selective EGFRL858R/T790M/C797S inhibitors. A representative compound, 8r-B, exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being a significantly less potent for EGFRWT (IC50 &gt; 1.0 μM). Cocrystallographic structure determination and computational investigation were conducted to elucidate its target selectivity.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00576&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00576" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00576&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00576" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00576&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00576" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00576&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00576&amp;href=/doi/10.1021/acs.jmedchem.9b00576" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00576" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00576" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26pmid%3D31298540%26genre%3Darticle%26aulast%3DShen%26date%3D2019%26atitle%3DStructure-Based%2BDesign%2Bof%2B5-Methylpyrimidopyridone%2BDerivatives%2Bas%2BNew%2BWild-Type%2BSparing%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTriple%2BMutant%2B%2528EGFRL858R%252FT790M%252FC797S%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/jmcmar.2019.62.issue-15/20190808/jmcmar.2019.62.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tertiary EGFR<sup>C797S</sup> mutation induced resistance against osimertinib (<b>1</b>) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selective EGFR<sup>L858R/T790M/C797S</sup> inhibitors. A representative compound, <b>8r-B</b>, exhibited an IC<sub>50</sub> of 27.5 nM against the EGFR<sup>L858R/T790M/C797S</sup> mutant, while being a significantly less potent for EGFR<sup>WT</sup> (IC<sub>50</sub> > 1.0 μM). Cocrystallographic structure determination and computational investigation were conducted to elucidate its target selectivity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The epidermal growth factor receptor (EGFR) has been well validated as a therapeutic target for anticancer drug discovery.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Three generations of EGFR inhibitors, e.g., reversible gefitinib<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and erlotinib,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> irreversible afatinib<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and dacomitinib,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> and the wild-type sparing osimertinib (<b>1</b>, AZD9291),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> have been approved by the U.S. FDA and have achieved significant clinical benefit for NSCLC patients with EGFR activating mutations (i.e., L858R and delE746-A750) and/or secondary threonine<sup>790</sup> to methionine<sup>790</sup> (T790M) mutation, respectively. In particular, drug <b>1</b> has become the first globally accessible third-generation EGFR inhibitor, having been recently approved as a first-line treatment for metastatic NSCLC patients,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> representing one of the most advanced developments in NSCLC therapy.</div><div class="NLM_p">Mode of action (MOA) investigation revealed that the acrylamide moiety in drug <b>1</b> could undergo a Michael addition reaction with the side chain of the Cys<sup>797</sup> residue under physiological conditions to increase the target residence time and restore inhibitory activity against the EGFR<sup>T790M</sup> mutants.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> However, a tertiary Cys<sup>797</sup> to Ser<sup>797</sup> (C797S) point mutation becomes a leading mechanism of clinically acquired resistance in ∼40% of drug <b>1</b> treated NSCLC patients, by disturbing the corresponding covalent bond formation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Accordingly, development of selective EGFR<sup>C797S</sup> inhibitors is considered as a new potential strategy to overcome acquired resistance against the third-generation EGFR inhibitors.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a></div><div class="NLM_p">Recently, an allosteric inhibitor EAI045 (<b>2a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was discovered that selectively exhibits low nM IC<sub>50</sub> potency against the EGFR<sup>C797S</sup> mutant. However, combination with an EGFR antibody, e.g. cetuximab, was required for the compound to demonstrate in vivo therapeutic efficacy, because of asymmetric dimerization of the EGFR receptor.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Brigatinib (<b>3</b>) and <b>4</b> and <b>5</b> were also reported to display strong ATP-competitive inhibition against EGFR<sup>C797S</sup>. Similar to the allosteric inhibitor <b>2a</b>, drug <b>3</b> also required combination with cetuximab to display in vivo efficacy in xenograft mouse models with EGFR<sup>C797S</sup> mutations.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compound <b>5</b> represents one of the most selective ATP-competitive inhibitors of EGFR<sup>C797S</sup> reported; however no in vitro or in vivo efficacy data have been disclosed to date.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Most recently, JBJ-04-125-02 (<b>2b</b>) was disclosed as a new allosteric inhibitor of the EGFR<sup>L858R/T790M/C797S</sup> mutant with promising in vitro and in vivo efficacy. However, the molecule is inactive against the clinically important EGFR<sup>Del-19</sup> variants (e.g., EGFR<sup>delE746-A750</sup>, EGFR<sup>delE746-A750/T790M</sup>, and EGFR<sup>delE746-A750/T790M/C797S</sup>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We have also identified a pyrimidopyrimidinone derivative, JND3229 (<b>6</b>), as a new reversible EGFR<sup>C797S</sup> mutant inhibitor with in vitro and in vivo single-agent efficacy, but its relatively low EGFR<sup>L858R/T790M/C797S</sup> target specificity over the wild-type kinase may raise some concern about potential EGFR mechanism-related toxicity.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of osimertinib and the reported EGFR<sup>C797S</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper, we describe the design and synthesis of a series of 5-methylpyrimidopyridone derivatives as new wild-type sparing EGFR<sup>L858R/T790M/C797S</sup> inhibitors. X-ray cocrystallographic structure determination and computational investigation were employed to rationalize the target selectivity of the molecules.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Molecular Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Structural feature analysis of the <b>6</b>-EGFR<sup>T790M/C797S</sup> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>) revealed that the compound bound to the ATP-binding pocket with a similar “U-shaped” configuration to that of our previously reported EGFR<sup>T790M</sup> selective inhibitor <b>7</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Previous studies also demonstrated that the 5-methyl substituent of <b>7</b> was directed toward the “gatekeeper” residue Met<sup>790</sup>, contributing greatly to EGFR<sup>T790M</sup> selectivity over the wild-type protein.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A preliminary superimposition further suggested that the 5-methylpyrido[2,3-<i>d</i>]pyrimidin-7-one scaffold of the irreversible inhibitor <b>7</b><a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> overlapped with the pyrimido[4,5-<i>d</i>]pyrimidine-7-one core of <b>6</b> in the EGFR<sup>T790M/C797S</sup> complex. On the basis of these observations, a series of 5-methylpyrimidopyridone derivatives (<b>8</b>) were designed and synthesized as new potential EGFR<sup>L858R/T790M/C797S</sup> inhibitors, with the aim of improving the target selectivity of this class of derivatives over wild-type EGFR (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure-based design of new EGFR<sup>L858R/T790M/C797S</sup> inhibitors: (A) chemical structure of <b>6</b> and its complex with EGFR<sup>T790M/C797S</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>); (B) chemical structure of <b>7</b> and its complex with EGFR<sup>T790M</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>); (C) superimposition of <b>7</b> with inhibitor <b>6</b> in EGFR<sup>T790M/C797S</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>); (D) designed new EGFR<sup>L858R/T790M/C797S</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The designed molecules <b>8a</b>–<b>r</b> were readily synthesized by using a protocol outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, commercially available 5-bromo-2,4-dichloropyrimidine <b>9</b> was reacted with protected aliphatic amines <b>10</b> to obtain <b>11</b>. Compounds <b>11</b> were condensed with <i>trans</i>-but-2-enoic acid under Heck coupling conditions<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> in the presence of bis(benzonitrile)palladium(II) dichloride before being treated with acetic anhydride to produce intermediates <b>12</b>. Selective bromination of intermediates <b>12</b> with liquid bromine in acetic acid gave <b>13</b>. Compounds <b>13</b> were coupled with 3-methyl-4-(4-methylpiperazin-1-yl)aniline to produce intermediates <b>14</b>. Intermediates <b>14</b> underwent Suzuki coupling with a range of phenylboronic acids to give <b>15</b> which were deprotected under acidic conditions to yield the substituted amines <b>16</b>. With <b>16</b> in hand, designed molecules <b>8a</b>,<b>c</b>–<b>r</b> were easily prepared by a standard acylation reaction. Alternatively, synthetic procedures for <b>8b</b> and <b>8l</b> are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>8a</b>,<b>c</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, acetonitrile (AN), 0 °C to rt, 80–95%; (b) (i) (<i>E</i>)-but-2-enoic acid, bis(benzonitrile)palladium(II) dichloride, DIPEA, tri(<i>o</i>-tolyl)phosphine, THF, 80 °C, argon, 16 h, (ii) acetic anhydride, 90 °C, 24 h, 40–50%; (c) Br<sub>2</sub>, AcONa, AcOH, 50 °C, 30 h, 60–75%; (d) 3-methyl-4-(4-methylpiperazin-1-yl)aniline, TFA, 2-butanol, 110 °C, 18 h, 50–65%; (e) [(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>P]<sub>2</sub>PdCl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, substituted phenylboronic acid, 1,4-dioxane, H<sub>2</sub>O, 110 °C, 45–70%; (f) TFA, DCM, rt, 85–90%; (g) propionyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 80–90%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>8a</b>, in which the original pyrimido[4,5-<i>d</i>]pyrimidine-7-one core of <b>6</b> was simply replaced by a 5-methylpyrido[2,3-<i>d</i>]pyrimidin-7-one moiety, was first designed and synthesized. Its kinase inhibition activities against EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M/C797S</sup> were determined by utilizing an enzyme-linked immunosorbent assay (ELISA).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Four previously reported EGFR<sup>C797S</sup> inhibitors, i.e., <b>2</b>, <b>3</b>, <b>5</b>, and <b>6</b>, were included as the reference compounds. All of the positive control compounds exhibited IC<sub>50</sub> values comparable to the reported data.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19">(15−19)</a> Disappointingly, <b>8a</b> displayed obviously decreased potency with IC<sub>50</sub> of 180.9 and 519.9 nM against EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M/C797S</sup>, respectively, which was 27- to 90-fold less potent than the original lead molecule <b>6</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Preliminary computational investigation suggested that the 5-methyl group failed to extend to the gatekeeper Met<sup>790</sup> residue and form a favorable hydrophobic interaction but caused a steric collision with this residue. Removal of the 5-methyl group (<b>8b</b>) indeed improved the inhibitory potency against EGFR<sup>L858R/T790M/C797S</sup> by a factor of 13.6-fold. However, eliminating the methyl group resulted in a greater potency improvement against EGFR<sup>WT</sup>, becoming detrimental to the target selectivity of the molecule. The resulting <b>8b</b> exhibited IC<sub>50</sub> of 3.8 and 38.1 nM against EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M/C797S</sup>, respectively. These results implied that introduction of a 5-methyl group could be beneficial for the design of wild-type sparing EGFR<sup>L858R/T790M/C797S</sup> inhibitors, although it might have a negative impact on the EGFR<sup>C797S</sup> inhibitory potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Kinase Inhibition of <b>8a</b>–<b>r</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0007.gif" alt="" id="GRAPHIC-d7e949-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">kinase inhibition (IC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">kinase inhibition (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">EGFR<sup>WT</sup></th><th class="colsep0 rowsep0" align="center">EGFR<sup>TM</sup></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">EGFR<sup>WT</sup></th><th class="colsep0 rowsep0" align="center">EGFR<sup>TM</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">2′- or 6′-Cl (mixture)</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">180.9 ± 80.8</td><td class="colsep0 rowsep0" align="left">519.9 ± 83.4</td><td class="colsep0 rowsep0" align="left"><b>8l-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Br</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">498.1 ± 126.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">2′- or 6′-Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3.8 ± 2.1</td><td class="colsep0 rowsep0" align="left">38.1 ± 10.1</td><td class="colsep0 rowsep0" align="left"><b>8l-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">6′-Br</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">56.1 ± 9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">2′- or 6′-Cl (mixture)</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">176.6 ± 80.6</td><td class="colsep0 rowsep0" align="left">35.1 ± 6.8</td><td class="colsep0 rowsep0" align="left"><b>8m-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">587.6 ± 111.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c-A</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">2′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">518.8 ± 78.1</td><td class="colsep0 rowsep0" align="left"><b>8m-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">6′-Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">227.9 ± 9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c-B</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">168.8 ± 63.4</td><td class="colsep0 rowsep0" align="left">27.7 ± 10.3</td><td class="colsep0 rowsep0" align="left"><b>8n</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′- or 6′-OMe (mixture)</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">2′- or 6′-Cl (mixture)</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">280.5 ± 39.5</td><td class="colsep0 rowsep0" align="left">866.9 ± 146.4</td><td class="colsep0 rowsep0" align="left"><b>8o</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′- or 6′-OH (mixture)</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e-A</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="left">2′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>8p-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Cl, 5′-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">207.0 ± 135.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e-B</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="left">6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>8p-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">3′-F, 6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">37.1 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>8q-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Cl,4′-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">224.1 ± 6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">65.1 ± 22.7</td><td class="colsep0 rowsep0" align="left"><b>8q-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">4′-F, 6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">88.6 ± 13.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g-A</b></td><td class="colsep0 rowsep0" align="left">VI</td><td class="colsep0 rowsep0" align="left">2′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>8r-A</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′-Cl, 3′-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g-B</b></td><td class="colsep0 rowsep0" align="left">VI</td><td class="colsep0 rowsep0" align="left">6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">81.7 ± 23.3</td><td class="colsep0 rowsep0" align="left"><b>8r-B</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">5′-F, 6′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">27.5 ± 11.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8h</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">3′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">73.1 ± 12.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">4′-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">76.6 ± 20.2</td><td class="colsep0 rowsep0" align="left">3.0 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8j</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">38.7 ± 16.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8k</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">2′- or 6′-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.8 ± 3.8</td><td class="colsep0 rowsep0" align="left">5.8 ± 2.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">EGFR<sup>L858R/T790M/C797S</sup> (EGFR<sup>TM</sup>) and EGFR<sup>WT</sup> kinase inhibition was tested by ELISA assay. The data are mean values from at least three independent experiments.</p></div></div></div><div class="NLM_p">Our next investigation mainly focused on identification of an optimal R<sub>1</sub>-linker group, which could potentially facilitate the 5-methyl substituent to adopt a suitable orientation avoiding steric collision with Met<sup>790</sup>. The propionamide was kept unchanged because the <b>6</b>-EGFR<sup>T790M/C797S</sup> complex structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>) suggested that this moiety was solvent-surface accessible and might not make much contribution to interaction with the protein. Interestingly, a replacement of the <i>trans</i>-cyclohexanediamine linker in <b>8a</b> with a <i>cis</i>-cyclohexanediamine moiety (<b>8c</b>) resulted in a significant improvement in EGFR<sup>L858R/T790M/C797S</sup> inhibitory potency. The resulting <b>8c</b> exhibited an IC<sub>50</sub> of 35.1 nM against EGFR<sup>L858R/T790M/C797S</sup>, which is 14.8-fold more potent than the parental compound <b>8a</b>. However, the modification barely affected the inhibitory activity against EGFR<sup>WT</sup>. The steric hindrance between the 5-methyl and 7-carbonyl moieties of the scaffold and the 2′-Cl group of the pendent phenyl ring of <b>8c</b> results in hindered rotation of the corresponding C–C bond, inducing an axial chirality in the molecule. Two atropisomers present in the mixture <b>8c</b> (i.e., <b>8c-A</b> and <b>8c-B</b>) were separated by chiral high performance liquid chromatography (HPLC). The absolute stereochemistry of both compounds was determined by using small molecule X-ray crystallographic analysis (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Further biological evaluation revealed that the compounds exhibited IC<sub>50</sub> of 518.8 and 27.7 nM against EGFR<sup>L858R/T790M/C797S</sup>, respectively. Thus, <b>8c-B</b> represents the preferred configuration to bind with the triple mutant.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>8c-A</b> and <b>8c-B</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several other aliphatic heterocyclic linkers were also explored (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Although introduction of 4-piperidine (<b>8d</b>) or (<i>S</i>)-3-piperidine (<b>8e-A</b> and <b>8e-B</b>) linkers caused total abolishment of the EGFR<sup>L858R/T790M/C797S</sup> inhibitory potency, the (<i>R</i>)-3-piperidine substituted molecule <b>8f-B</b> and the(<i>R</i>)-3-pyrrolidine derivative <b>8g-B</b> exhibited IC<sub>50</sub> of 65.1 and 81.7 nM, respectively, against the EGFR<sup>L858R/T790M/C797S</sup> mutant. Notably, <b>8f-B</b> and <b>8g-B</b> were almost equally potent to <b>8b</b> and <b>8c</b>, but their inhibition of the wild-type kinase was abolished. Similar to the above observation, the alternate stereoenantiomers <b>8f-A</b> and <b>8g-A</b> were totally inactive. Consequently, <b>8f-B</b> was selected as a new starting point for further structural optimization because of its relatively potent EGFR<sup>L858R/T790M/C797S</sup> inhibition and promising target selectivity.</div><div class="NLM_p">Our previous structural investigation implied that a 2′-chloro group in <b>6</b> might be critical to force the pendent phenyl moiety to adopt an appropriate orientation for it to be accommodated in a hydrophobic pocket bounded by Lys<sup>745</sup>, Glu<sup>762</sup>, Leu<sup>788</sup>, Met<sup>766</sup>, and Met<sup>790</sup> in EGFR<sup>C797S</sup>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> To validate the potential contribution of the 2′-chloro group of <b>8f-B</b>, compounds <b>8h</b> and <b>8i</b>, in which the chloro-substituent was moved to the 3′-position and 4′-position, respectively, were design and synthesized. <b>8h</b> and <b>8i</b> were totally inactive with respect to inhibition of EGFR<sup>L858R/T790M/C797S</sup> and EGFR<sup>WT</sup>, supporting our hypothesis that a 2′-substituent is optimal for inhibition of the EGFR kinase. Not surprisingly, removal of the critical 2′-chloro group also caused a total abolishment of inhibitory activity against EGFR<sup>WT</sup> and the C797S mutant (<b>8j</b>). Further investigation revealed that this position is highly sensitive to the size and physicochemical properties of the substituted group. When the 2′-chloro substituent was replaced with 2′-fluoro (<b>8k</b>), 2′-methoxyl (<b>8n</b>), or 2′-hydroxyl (<b>8o</b>) groups, all of the resulting molecules were found to be completely inactive against EGFR<sup>L858R/T790M/C797S</sup> and EGFR<sup>WT</sup>. The 2′-methyl analogs (i.e., <b>8m-A</b> and <b>8m-B</b>) were also notably less active than <b>8f-B</b>. Not surprisingly, the 2′-bromo derivative (<b>8l-B</b>) exhibited similar EGFR<sup>L858R/T790M/C797S</sup> inhibitory potency to that of <b>8f-B</b>, with an IC<sub>50</sub> of 56.1 nM. Interestingly, introduction of a second fluoro substituent at each available vacant position of the pendent chlorophenyl ring had varying influence on the biological activity of the molecules. For instance, the 4′-F, 6′-Cl disubstituted analog (<b>8q-B</b>) exhibited almost identical potency and selectivity to that of <b>8f-B</b>, but the 3′-F, 6′-Cl (<b>8q-B</b>) and 5′-F, 6′-Cl (<b>8r-B</b>) were 1.8- to 2.4-fold more potent than the lead molecule. Compounds <b>8q-B</b> and <b>8r-B</b> exhibited IC<sub>50</sub> of 37.1 and 27.5 nM, respectively, against the EGFR<sup>L858R/T790M/C797S</sup> mutant. It was also noteworthy that <b>8r-B</b> and <b>8q-B</b> were equally potent and selective to the previously reported EGFR<sup>C797S</sup> inhibitor <b>5</b> in a parallel comparison. Different from the allosteric inhibitor <b>2b</b>, <b>8r-B</b> exhibited similar inhibition against the EGFR<sup>del746-750/T790M/C797S</sup> mutant with an IC<sub>50</sub> of 49.9 nM.</div><div class="NLM_p">X-ray cocrystallographic structures of <b>8r-B</b> with EGFR<sup>T790M/C797S</sup> and EGFR<sup>WT</sup> were further determined to elucidate detailed interactions and the structural basis of the observed target selectivity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). These confirmed that <b>8r-B</b> bound at the ATP binding sites of EGFR<sup>T790M/C797S</sup> and EGFR<sup>WT</sup> with similar “U-shaped” configurations. The 5-methylpyrimidopyrimidinone scaffold formed the classical hydrogen bond donor–acceptor interactions with the “hinge” residue Met<sup>793</sup>, while the 6-(2′-chloro-3′-fluoro)phenyl group occupies a hydrophobic pocket bounded by Lys<sup>745</sup>, Glu<sup>762</sup>, Leu<sup>788</sup>, Met<sup>766</sup>, and Met<sup>790</sup>. The 4-methylpiperazinylphenyl group and the propionylpiperidine were directly accessible to the solvent surface, which would provide feasible positions for future optimization of the physicochemical properties of the compounds. Notably, the 5-methyl group approaches Met<sup>790</sup> within a distance of 3.5 Å in EGFR<sup>T790M/C797S</sup> to form a favorable hydrophobic interaction. Alternatively, its lipophilic character appears to be incompatible with the hydrophilic Thr<sup>790</sup> in EGFR<sup>WT</sup>. In addition, the lipophobic property of Thr<sup>790</sup> could also weaken the hydrophobic interactions of the 6-(2′-chloro-3′-fluoro)phenyl group with wild-type EGFR. This structural information could provide a rational explanation for the inhibitor’s selectivity between EGFRT<sup>790M/C797S</sup> and EGFR<sup>WT</sup>.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structures of cocrystals of <b>8r-B-</b>EGFR<sup>T790M/C797S</sup> and <b>8r-B</b>-EGFR<sup>WT</sup> complexes: (A) 2.943 Å crystallographic structure of <b>8r-B</b>-EGFR<sup>T790M/C797S</sup> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>); (B) 2.796 Å crystallographic structure of <b>8r-B</b>-EGFRT<sup>WT</sup> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK">6JRK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding free energies of <b>8r-B</b> in EGFR<sup>WT</sup> and the EGFR<sup>T790M/C797S</sup> mutant were estimated to be −47.8 ± 2.7 kcal/mol and −57.5 ± 4.0 kcal/mol, respectively, by utilizing classical MD simulations and MM-GBSA calculations (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>). These results suggest that binding of <b>8r-B</b> to EGFR<sup>T790M/C797S</sup> is thermodynamically more favorable than binding to EGFR<sup>WT</sup>, which is consistent with the experimental results. Moreover, contribution of the stabilization energy of each residue to the overall binding affinity of <b>8r-B</b> was also evaluated and the difference between the EGFR<sup>WT</sup> and EGFR<sup>T790M/C797S</sup> mutant was calculated using the equation ΔΔ<i>G</i> = Δ<i>G</i><sub>WT</sub> – Δ<i>G</i><sub>TMCS</sub>. The top 10 significant residues to enhance the binding affinity are summarized in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. The binding energy difference (ΔΔ<i>G</i> = Δ<i>G</i><sub>WT</sub> – Δ<i>G</i><sub>T790M/C797S</sub>) of <b>3</b> and <b>6</b> were also calculated to be −1.5 and 2.2 kcal/mol, respectively, which might give a reasonable explanation for their relatively low triple mutant selectivity (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Hydrophobic amino acid residues are marked in dark green, while the polar amino acid residues are marked in red. (B) Top 10 hot-spot residues predicted computationally.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further biological investigation validated that <b>8r-B</b> potently suppressed the activation of EGFR signaling in BaF3 cells stably transfected with EGFR<sup>L858R/T790M/C797S</sup> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>) and inhibited proliferation of this transfected cell line model with an IC<sub>50</sub> of 0.662 ±0.045 μM. However, its effect on wild-type EGFR signaling was significantly less obvious (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>). Investigation also revealed that the compound exhibited moderate aqueous solubility and cellular permeability (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of 5-methylpyrimidopyridone derivatives were designed and synthesized as novel selective wild-type sparing EGFR<sup>L858R/T790M/C797S</sup> inhibitors. One of the representative compounds, <b>8r-B</b>, exhibited an IC<sub>50</sub> of 27.5 nM against the EGFR<sup>L858R/T790M/C797S</sup> triple mutant while being almost totally inactive against the EGFR<sup>WT</sup> kinase, identifying <b>8r-B</b> as one of the most selective fourth generation EGFR inhbitors reported to date. Cocrystallographic structure determination and computational investigation further validated that target selectivity of the inhibitors mainly relied on the hydrophobic nature of the Met<sup>790</sup> residue in the T790M/C797S mutant protein. Although the relatively low kinome selectivity and metabolic liability (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>) of <b>8r-B</b> may limit its future development, our study provides a useful lead compound and some fundmental structural information for the rational development of new selective EGFR<sup>C797S</sup> inhibitor drugs. Further pharmacokinetics-oriented optimization of <b>8r-B</b> is ongoing, and the results will be disclosed in due course.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> General Chemistry</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial suppliers and used without further purification. Flash chromatography was performed using silica gel (200–300 mesh). All reactions were monitored by TLC, using silica gel plates with fluorescence F254 and UV light visualization. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz and Bruker AV-500 spectrometer at 125 MHz, respectively. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to internal control (TMS). The first-order peak patterns are indicated as s (singlet), d (doublet), t (triplet), q (quadruplet). Complex non-first-order signals are indicated as m (multiplet). The low- or high-resolution ESI-MS results were recorded on an Agilent 1200 HPLC-MSD mass spectrometer or Applied Biosystems Q-STAR Elite ESILC-MS/MS mass spectrometer, respectively. The purity of compounds was determined by reverse-phase high-performance liquid chromatography (HPLC) analysis, confirming to be >95%. Analytical HPLC analyses were conducted using an Agilent 1260 system (G1310B Iso pump and G1365D MWD VL detector) with an YMC-Triart C18 reversed-phase column (250 mm × 4.6 mm, 5 μm) at 254 nm. Elution was MeOH in water, and flow rate was 1.0 mL/min. Preparative HPLC (PHPLC) purifications were performed using Agilent 218 solvent delivery module and an Agilent 325 dual wavelength UV–vis detector with an YMC-Triart C18 reversed-phase column (250 mm × 20 mm, 5 μm) at 254 nm. The LC column was maintained at room temperature.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>N</i>-((1<i>R</i>,4<i>R</i>)-4-(6-(2-Chlorophenyl)-5-methyl-2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-<i>d</i>]pyrimidin-8(7<i>H</i>)-yl)cyclohexyl)propionamide (<b>8a</b>)</h3><div class="NLM_p">Propionyl chloride (25 μL, 0.28 mmol) was added dropwise to a mixture of <b>16a</b> which was readily prepared by a protocol described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a> (150 mg, 0.26 mmol) and Et<sub>3</sub>N (0.11 mL, 0.78 mmol) in dry DCM (10 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography to afford <b>8a</b> as a yellow solid (135 mg, 92%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.87 (s, 1H), 8.89 (s, 1H), 7.60 (d, <i>J</i> = 2.3 Hz, 1H), 7.57–7.53 (m, 1H), 7.49 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.41 (dd, <i>J</i> = 4.6, 2.3 Hz, 2H), 7.31–7.24 (m, 1H), 7.02 (d, <i>J</i> = 8.7 Hz, 1H), 5.42 (s, 1H), 3.86 (s, 1H), 2.81 (s, 5H), 2.47 (s, 4H), 2.28 (s, 3H), 2.23 (s, 3H), 2.15 (d, <i>J</i> = 7.4 Hz, 1H), 2.12 (s, 3H), 1.91 (d, <i>J</i> = 11.1 Hz, 2H), 1.55 (d, <i>J</i> = 9.1 Hz, 2H), 1.42 (s, 2H), 1.24 (d, <i>J</i> = 11.1 Hz, 3H), 1.01–0.92 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.5, 162.8 (2C), 161.9, 159.2, 157.8, 155.2, 135.5, 134.0 (2C), 132.7, 132.5 (2C), 129.9, 129.5 (2C), 127.5, 119.4, 119.1, 106.7, 106.6, 55.7 (2C), 51.8, 46.2, 36.3, 32.7, 31.2, 29.5, 29.4, 29.0, 28.5, 27.1, 18.4, 15.1, 10.5. HRMS (ESI) for C<sub>35</sub>H<sub>42</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 628.3089; found, 628.3218. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.86 min, 97.3% purity.</div><div class="NLM_p last">The other designed compounds were synthesized by following a similar procedure (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00576" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00576" class="ext-link">10.1021/acs.jmedchem.9b00576</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic procedures, in vitro ELISA assay, cell proliferation inhibition assay, Western blot analysis, experimental data for the X-ray structures of <b>8c-A</b> and <b>8c-B</b>, computational study, solubility assay, metabolic stability, Caco-2 permeability assay, the kinase selectivity profiling study of <b>8r-B</b>, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <b>8a</b>–<b>r</b>, and HPLC purity analysis of <b>8a</b>–<b>r</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Characterization checklist (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_003.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf">jm9b00576_si_001.pdf (8.53 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_002.csv">jm9b00576_si_002.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_003.xlsx">jm9b00576_si_003.xlsx (44.9 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00576" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cai-Hong Yun</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics, Institute of Systems Biomedicine,
School of Basic Medical Sciences, Peking
University Health Science Center, Beijing 100191, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-8307" title="Orcid link">http://orcid.org/0000-0002-5880-8307</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b1c8c4dfd2d9f1d3dbdcc49fd4d5c49fd2df"><span class="__cf_email__" data-cfemail="bcc5c9d2dfd4fcded6d1c992d9d8c992dfd2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Xie</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3dbcbdad6f3c0dadede9dd2d09dd0dd"><span class="__cf_email__" data-cfemail="0f6777666a4f7c666262216e6c216c61">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d6baa3aeafe4e6e7e096bcb8a3f8b3b2a3f8b5b8"><span class="__cf_email__" data-cfemail="7519000d0c47454443351f1b005b1011005b161b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#680c01060f030d2802061d460d0c1d460b06"><span class="__cf_email__" data-cfemail="91f5f8fff6faf4d1fbffe4bff4f5e4bff2ff">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiayi Shen</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Zhang</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Jie Zhu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Translational Medicine, College of Medicine, Qingdao University, Qingdao 266021, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Sun</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Aosaikang Pharmacceutical Co. Ltd., No. 699 Kejian Road, Jiangsu Science Park, Nanjing 211112, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linjiang Tong</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengzhen Lai</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Sun Yat-sen
University, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Xu</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruibo Wu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Sun Yat-sen
University, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.S., T.Z., and S.-j.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Atomic coordinates and experimental data for the cocrystal structures of <b>8r-B</b> with EGFR<sup>T790M/C797S</sup> and EGFR<sup>WT</sup> will be released upon article publication.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial support from National Natural Science Foundation of China (Grants 81820108029, 21572230, 81673285, 81425021, 21702075), Guangdong Province (Grants 2015A030312014, 2015A030306042, 2016A050502041, 2018A050506043, and 2017A030310253), Guangzhou City (Grant 201805010007), and Jinan University. We also thank Profs. Jeff Smaill and Adam Patterson from the University of Auckland, New Zealand, for proofreading our manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">C797S</td><td class="NLM_def"><p class="first last">Cys797 to Ser797</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mode of action</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">AN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 24 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunpaweravong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margono, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=L.+Y.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=H.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0litduMuMi-N7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DL.%2BY.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhsXZ9I7YeP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Erlotinib hydrochloride</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1038/nrd1612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnrd1612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=15690599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2n" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=13-14&author=J.+Dowellauthor=J.+D.+Minnaauthor=P.+Kirkpatrick&title=Erlotinib+hydrochloride&doi=10.1038%2Fnrd1612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the Pipeline: Erlotinib hydrochloride</span></div><div class="casAuthors">Dowell, Jonathan; Minna, John D.; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-14</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in Nov. 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen.  It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5f2xcaVEnrVg90H21EOLACvtfcHk0lhsXZ9I7YeP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2n&md5=acb463aa1a7ad35b770490a7c82800cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1612%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DErlotinib%2520hydrochloride%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D13%26epage%3D14%26doi%3D10.1038%2Fnrd1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0lhsXZ9I7YeP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.+L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+versus+gefitinib+as+first-line+treatment+for+patients+with+EGFR-mutation-positive+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0li1u4h_cfTLnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520versus%2520gefitinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520EGFR-mutation-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido3,4-dpyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido3%2C4-dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0li1u4h_cfTLnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido3%252C4-dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lhidSbYyWIM3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimetinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimetinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lhidSbYyWIM3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimetinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>FDA Center
for Drug Evaluation and Research. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf" class="extLink">www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf</a> (accessed April 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Center%0Afor+Drug+Evaluation+and+Research.+www.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F208065s008lbl.pdf+%28accessed+April+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+underlies+the+emergence+of+EGFRT790+wild-type+clones+following+treatment+of+T790M-positive+cancers+with+a+third-generation+EGFR+inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0lizf4WlVz5Iqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520underlies%2520the%2520emergence%2520of%2520EGFRT790%2520wild-type%2520clones%2520following%2520treatment%2520of%2520T790M-positive%2520cancers%2520with%2520a%2520third-generation%2520EGFR%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lizf4WlVz5Iqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0ljhapgYDZ2a1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljhapgYDZ2a1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.+M.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhyWg_us_tMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BM.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EGFR c797s mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0290-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1186%2Fs13045-016-0290-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27448564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=59-64&author=S.+Wangauthor=S.+T.+Tsuiauthor=C.+Liuauthor=Y.+Songauthor=D.+Liu&title=EGFR+c797s+mutation+mediates+resistance+to+third-generation+inhibitors+in+T790M-positive+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0290-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Tsui, Stella T.; Liu, Christina; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59/1-59/5</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR).  Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance.  AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-pos. non-small cell lung cancer.  Resistance to AZD9291 has been described.  C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors.  This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJ4ifH6CVz7Vg90H21EOLACvtfcHk0lhyWg_us_tMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK&md5=f1c69b429f08a527b9a20bdd567fe21a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0290-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0290-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEGFR%2520c797s%2520mutation%2520mediates%2520resistance%2520to%2520third-generation%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D59%26epage%3D64%26doi%3D10.1186%2Fs13045-016-0290-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayeni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Emerging agents and new mutations in EGFR-mutant lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3818</span>– <span class="NLM_lpage">3820</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F1078-0432.CCR-15-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=26169963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3818-3820&author=D.+Ayeniauthor=K.+Politiauthor=S.+D.+Goldberg&title=Emerging+agents+and+new+mutations+in+EGFR-mutant+lung+cancer&doi=10.1158%2F1078-0432.CCR-15-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Ayeni, Deborah; Politi, Katerina; Goldberg, Sarah B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3818-3820</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clin. activity, particularly in lung cancers harboring the EGFRT790M mutation, yet acquired resistance to these agents emerges.  Addnl. mutations in EGFR can confer resistance that, depending on their genomic context, could det. new drug sensitivities of the cancer cells.  Clin Cancer Res; 21(17); 3818-20. ©2015 AACR.  See related articles by Ercan et al., p. 3913 and Niederst et al., p.  3924.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe_EGwPDRgUrVg90H21EOLACvtfcHk0lhyWg_us_tMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLbK&md5=66baccd27ceee6ad6078f85d78eaf65f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1211%26sid%3Dliteratum%253Aachs%26aulast%3DAyeni%26aufirst%3DD.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DEmerging%2520agents%2520and%2520new%2520mutations%2520in%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3818%26epage%3D3820%26doi%3D10.1158%2F1078-0432.CCR-15-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0ljIMOJtbwwQAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>– <span class="NLM_lpage">14784</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768-14784&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0ljIMOJtbwwQAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26epage%3D14784%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2eYjeVL2FaWLCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGFR (d746-750/T790M/C797S) mutant-selective inhibitors via structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGFR+%28d746-750%2FT790M%2FC797S%29+mutant-selective+inhibitors+via+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0liNM9RbjjKUMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGFR%2520%2528d746-750%252FT790M%252FC797S%2529%2520mutant-selective%2520inhibitors%2520via%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+dual+targeting+of+mutant+EGFR+with+an+allosteric+inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0liNM9RbjjKUMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520dual%2520targeting%2520of%2520mutant%2520EGFR%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a new EGFR<sup>C797S</sup> mutant inhibitor with <i>in vivo</i> monodrug efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+new+EGFRC797S+mutant+inhibitor+with+in+vivo+monodrug+efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0lj7J5pa53J16A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520new%2520EGFRC797S%2520mutant%2520inhibitor%2520with%2520in%2520vivo%2520monodrug%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span> <span> </span><span class="NLM_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR<sup>L858R/T790M</sup> mutant with improved pharmacokinetic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1016%2Fj.ejmech.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28033579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=1107-1117&author=L.+Yuauthor=M.+H.+Huangauthor=T.+F.+Xuauthor=L.+J.+Tongauthor=X.+Y.+Yanauthor=Z.+Zhangauthor=Y.+Xuauthor=C.+H.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Y.+Lu&title=A+structure-guided+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+selective+inhibitors+of+EGFRL858R%2FT790M+mutant+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.ejmech.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties</span></div><div class="casAuthors">Yu, Lei; Huang, Minhao; Xu, Tianfeng; Tong, Linjiang; Yan, Xiao-e; Zhang, Zhang; Xu, Yong; Yun, Caihong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1107-1117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790M inhibitors with improved pharmacokinetic properties.  One of the most promising compd. 9s (N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide) potently suppressed EGFRL858R/T790M kinase and inhibited the proliferation of H1975 cells with IC50 values of 2.0 nM and 40 nM, resp.  The compd. dose-dependently induced redn. of the phosphorylation of EGFR and downstream activation of ERK in NCI-H1975 cells.  It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%.  Compd. 9s may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwni9j-NB9ZrVg90H21EOLACvtfcHk0lj7J5pa53J16A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D&md5=0c4c9ab1f2e5eba185d817161c3e261b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%2BH.%26aulast%3DXu%26aufirst%3DT.%2BF.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DYan%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%2BY.%26atitle%3DA%2520structure-guided%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520selective%2520inhibitors%2520of%2520EGFRL858R%252FT790M%2520mutant%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117%26doi%3D10.1016%2Fj.ejmech.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance related EGFR T790M mutant</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1039/C5MD00208G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1039%2FC5MD00208G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ygtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1693-1697&author=T.+F.+Xuauthor=T.+Pengauthor=X.+M.+Renauthor=L.+W.+Zhangauthor=L.+Yuauthor=J.+F.+Luoauthor=Z.+Zhangauthor=Z.+C.+Tuauthor=L.+J.+Tongauthor=Z.+R.+Huangauthor=X.+Y.+Luauthor=M.+Y.+Gengauthor=H.+Xieauthor=J.+Dingauthor=K.+Ding&title=C5-substituted+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+highly+specific+kinase+inhibitors+targeting+the+clinical+resistance+related+EGFR+T790M+mutant&doi=10.1039%2FC5MD00208G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant</span></div><div class="casAuthors">Xu, Tianfeng; Peng, Ting; Ren, Xiaomei; Zhang, Lianwen; Yu, Lei; Luo, Jinfeng; Zhang, Zhang; Tu, Zhengchao; Tong, Linjiang; Huang, Zhaoru; Lu, Xiaoyun; Geng, Meiyu; Xie, Hua; Ding, Jian; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1693-1697</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The development of specific kinase inhibitors has been a long-standing challenge in chem. biol. and drug discovery.  We have successfully discovered a series of C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific inhibitors against the clin. resistance-related EGFRT790M mutant.  One of the most promising compds., 9f, tightly binds to the EGFRT790M mutant and strongly inhibits its enzymic function with an IC50 value of 0.80 nM, and displays an extraordinary target specificity with S(35) and S(10) selectivity scores of 0.005 and 0.000, resp., in a kinase selectivity profiling study against 456 different kinases at 100 nM.  The compd. also selectively suppresses the proliferation of EGFRT790M mutated H1975 NSCLC cells with an IC50 value of 2.80 nM, but is significantly less toxic to cells with wild-type EGFR.  Compd. 9f may serve as a promising lead compd. for drug discovery overcoming the acquired resistance of NSCLC patients without adverse toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWwlWdk40U7Vg90H21EOLACvtfcHk0liEZBP6DI-aHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ygtbvE&md5=f2ad8e6a8b5a45fd078c83f9c502c68e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC5MD00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00208G%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%2BF.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DL.%2BW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.%2BC.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DHuang%26aufirst%3DZ.%2BR.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DC5-substituted%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520highly%2520specific%2520kinase%2520inhibitors%2520targeting%2520the%2520clinical%2520resistance%2520related%2520EGFR%2520T790M%2520mutant%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1693%26epage%3D1697%26doi%3D10.1039%2FC5MD00208G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Meng Cheng, Xufen Yu, Kaylene Lu, Ling Xie, Li Wang, Fanye Meng, Xiaoran Han, Xian Chen, Jing Liu, Yue Xiong, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1216-1232. <a href="https://doi.org/10.1021/acs.jmedchem.9b01566" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BBifunctional%252BSmall-Molecule%252BDegraders%26aulast%3DCheng%26aufirst%3DMeng%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19092019%26date%3D14012020%26date%3D02012020%26volume%3D63%26issue%3D3%26spage%3D1216%26epage%3D1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shengjin  Xia</span>, <span class="hlFld-ContribAuthor ">Qingqing  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113300. <a href="https://doi.org/10.1016/j.ejmech.2021.113300" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113300%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfamoylphenyl-quinazoline%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FCAIX%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DBin%26date%3D2021%26volume%3D216%26spage%3D113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prateek  Pathak</span>, <span class="hlFld-ContribAuthor ">Hrvoje  Rimac</span>, <span class="hlFld-ContribAuthor ">Maria  Grishina</span>, <span class="hlFld-ContribAuthor ">Amita  Verma</span>, <span class="hlFld-ContribAuthor ">Vladimir  Potemkin</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Quinazoline 1,3,5‐Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (5)
                                     , 822-838. <a href="https://doi.org/10.1002/cmdc.202000646" title="DOI URL">https://doi.org/10.1002/cmdc.202000646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000646%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DHybrid%252BQuinazoline%252B1%25252C3%25252C5%2525E2%252580%252590Triazines%252Bas%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bwith%252BAnticancer%252BActivity%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BComputational%252BStudy%26aulast%3DPathak%26aufirst%3DPrateek%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D5%26spage%3D822%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianheng  Li</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>, <span class="hlFld-ContribAuthor ">Xianheng  Song</span>, <span class="hlFld-ContribAuthor ">Qianzhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Chun  Chen</span>, <span class="hlFld-ContribAuthor ">Shuxian  Wei</span>, <span class="hlFld-ContribAuthor ">Runzhu  Fan</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFRL858R/T790M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113019. <a href="https://doi.org/10.1016/j.ejmech.2020.113019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaryl%252Bpyrimidine%252Bderivatives%252Bas%252Bselective%252BEGFRL858R%25252FT790M%252Binhibitors%26aulast%3DLi%26aufirst%3DJianheng%26date%3D2021%26volume%3D212%26spage%3D113019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Yongjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Xiaolu  Wang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yanhui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113023. <a href="https://doi.org/10.1016/j.ejmech.2020.113023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrido%25255B2%25252C%252B3-d%25255Dpyrimidin-7%2525288H%252529-ones%252Bas%252Bnew%252Bselective%252Borally%252Bbioavailable%252BThreonine%252BTyrosine%252BKinase%252B%252528TTK%252529%252Binhibitors%26aulast%3DHuang%26aufirst%3DMinhao%26date%3D2021%26volume%3D211%26spage%3D113023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Kewon  Kim</span>, <span class="hlFld-ContribAuthor ">Myojeong  Kim</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9323. <a href="https://doi.org/10.3390/ijms21239323" title="DOI URL">https://doi.org/10.3390/ijms21239323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239323%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DRational%252BComputational%252BDesign%252Bof%252BFourth-Generation%252BEGFR%252BInhibitors%252Bto%252BCombat%252BDrug-Resistant%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>, <span class="hlFld-ContribAuthor ">Arabinda  Ghosh</span>, <span class="hlFld-ContribAuthor ">Harun  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>3 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1844801" title="DOI URL">https://doi.org/10.1080/07391102.2020.1844801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3Dp38%2525CE%2525B1%252BMAP%252Bkinase%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Btertiary%252BC797S%252Bpoint%252Bmutation%252Bassociated%252Bwith%252Bosimertinib%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252Bemergence%252Bof%252Bfourth-generation%252BEGFR%252Binhibitor%26aulast%3DAhmad%26aufirst%3DIqrar%26date%3D2020%26date%3D2020%26volume%3D3%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingwen  E</span>, <span class="hlFld-ContribAuthor ">Ye  Liu</span>, <span class="hlFld-ContribAuthor ">Shanshan  Guan</span>, <span class="hlFld-ContribAuthor ">Zhijian  Luo</span>, <span class="hlFld-ContribAuthor ">Fei  Han</span>, <span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Song  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 895. <a href="https://doi.org/10.3390/molecules25040895" title="DOI URL">https://doi.org/10.3390/molecules25040895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25040895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25040895%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHow%252BDifferent%252BSubstitution%252BPositions%252Bof%252BF%25252C%252BCl%252BAtoms%252Bin%252BBenzene%252BRing%252Bof%252B5-Methylpyrimidine%252BPyridine%252BDerivatives%252BAffect%252Bthe%252BInhibition%252BAbility%252Bof%252BEGFRL858R%25252FT790M%25252FC797S%252BInhibitors%25253A%252BA%252BMolecular%252BDynamics%252BSimulation%252BStudy%26aulast%3DE%26aufirst%3DJingwen%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of osimertinib and the reported EGFR<sup>C797S</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure-based design of new EGFR<sup>L858R/T790M/C797S</sup> inhibitors: (A) chemical structure of <b>6</b> and its complex with EGFR<sup>T790M/C797S</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>); (B) chemical structure of <b>7</b> and its complex with EGFR<sup>T790M</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>); (C) superimposition of <b>7</b> with inhibitor <b>6</b> in EGFR<sup>T790M/C797S</sup> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>); (D) designed new EGFR<sup>L858R/T790M/C797S</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>8a</b>,<b>c</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, acetonitrile (AN), 0 °C to rt, 80–95%; (b) (i) (<i>E</i>)-but-2-enoic acid, bis(benzonitrile)palladium(II) dichloride, DIPEA, tri(<i>o</i>-tolyl)phosphine, THF, 80 °C, argon, 16 h, (ii) acetic anhydride, 90 °C, 24 h, 40–50%; (c) Br<sub>2</sub>, AcONa, AcOH, 50 °C, 30 h, 60–75%; (d) 3-methyl-4-(4-methylpiperazin-1-yl)aniline, TFA, 2-butanol, 110 °C, 18 h, 50–65%; (e) [(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>P]<sub>2</sub>PdCl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, substituted phenylboronic acid, 1,4-dioxane, H<sub>2</sub>O, 110 °C, 45–70%; (f) TFA, DCM, rt, 85–90%; (g) propionyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 80–90%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>8c-A</b> and <b>8c-B</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structures of cocrystals of <b>8r-B-</b>EGFR<sup>T790M/C797S</sup> and <b>8r-B</b>-EGFR<sup>WT</sup> complexes: (A) 2.943 Å crystallographic structure of <b>8r-B</b>-EGFR<sup>T790M/C797S</sup> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>); (B) 2.796 Å crystallographic structure of <b>8r-B</b>-EGFRT<sup>WT</sup> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK">6JRK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/medium/jm-2019-005766_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Hydrophobic amino acid residues are marked in dark green, while the polar amino acid residues are marked in red. (B) Top 10 hot-spot residues predicted computationally.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00576&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24586" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24586" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 24 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunpaweravong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margono, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=L.+Y.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=H.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lhCbEdElOIsZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DL.%2BY.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhyTSISw0ZAjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Erlotinib hydrochloride</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1038/nrd1612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnrd1612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=15690599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2n" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=13-14&author=J.+Dowellauthor=J.+D.+Minnaauthor=P.+Kirkpatrick&title=Erlotinib+hydrochloride&doi=10.1038%2Fnrd1612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the Pipeline: Erlotinib hydrochloride</span></div><div class="casAuthors">Dowell, Jonathan; Minna, John D.; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-14</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in Nov. 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen.  It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5f2xcaVEnrVg90H21EOLACvtfcHk0lhyTSISw0ZAjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2n&md5=acb463aa1a7ad35b770490a7c82800cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1612%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DErlotinib%2520hydrochloride%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D13%26epage%3D14%26doi%3D10.1038%2Fnrd1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0lhyTSISw0ZAjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.+L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+versus+gefitinib+as+first-line+treatment+for+patients+with+EGFR-mutation-positive+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lgIjdhpAMRq6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520versus%2520gefitinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520EGFR-mutation-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido3,4-dpyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido3%2C4-dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0lgIjdhpAMRq6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido3%252C4-dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lhAIp7vLUoMhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimetinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimetinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lhAIp7vLUoMhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimetinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>FDA Center
for Drug Evaluation and Research. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf" class="extLink">www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf</a> (accessed April 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Center%0Afor+Drug+Evaluation+and+Research.+www.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F208065s008lbl.pdf+%28accessed+April+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+underlies+the+emergence+of+EGFRT790+wild-type+clones+following+treatment+of+T790M-positive+cancers+with+a+third-generation+EGFR+inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0lgrkAYocY8Tfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520underlies%2520the%2520emergence%2520of%2520EGFRT790%2520wild-type%2520clones%2520following%2520treatment%2520of%2520T790M-positive%2520cancers%2520with%2520a%2520third-generation%2520EGFR%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lgrkAYocY8Tfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lgrkAYocY8Tfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljNVS9gVUBXbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.+M.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljNVS9gVUBXbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BM.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EGFR c797s mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0290-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1186%2Fs13045-016-0290-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27448564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=59-64&author=S.+Wangauthor=S.+T.+Tsuiauthor=C.+Liuauthor=Y.+Songauthor=D.+Liu&title=EGFR+c797s+mutation+mediates+resistance+to+third-generation+inhibitors+in+T790M-positive+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0290-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Tsui, Stella T.; Liu, Christina; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59/1-59/5</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR).  Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance.  AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-pos. non-small cell lung cancer.  Resistance to AZD9291 has been described.  C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors.  This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJ4ifH6CVz7Vg90H21EOLACvtfcHk0lhE_yCHpeuiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK&md5=f1c69b429f08a527b9a20bdd567fe21a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0290-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0290-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEGFR%2520c797s%2520mutation%2520mediates%2520resistance%2520to%2520third-generation%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D59%26epage%3D64%26doi%3D10.1186%2Fs13045-016-0290-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayeni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Emerging agents and new mutations in EGFR-mutant lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3818</span>– <span class="NLM_lpage">3820</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F1078-0432.CCR-15-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=26169963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3818-3820&author=D.+Ayeniauthor=K.+Politiauthor=S.+D.+Goldberg&title=Emerging+agents+and+new+mutations+in+EGFR-mutant+lung+cancer&doi=10.1158%2F1078-0432.CCR-15-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Ayeni, Deborah; Politi, Katerina; Goldberg, Sarah B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3818-3820</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clin. activity, particularly in lung cancers harboring the EGFRT790M mutation, yet acquired resistance to these agents emerges.  Addnl. mutations in EGFR can confer resistance that, depending on their genomic context, could det. new drug sensitivities of the cancer cells.  Clin Cancer Res; 21(17); 3818-20. ©2015 AACR.  See related articles by Ercan et al., p. 3913 and Niederst et al., p.  3924.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe_EGwPDRgUrVg90H21EOLACvtfcHk0lhE_yCHpeuiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLbK&md5=66baccd27ceee6ad6078f85d78eaf65f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1211%26sid%3Dliteratum%253Aachs%26aulast%3DAyeni%26aufirst%3DD.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DEmerging%2520agents%2520and%2520new%2520mutations%2520in%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3818%26epage%3D3820%26doi%3D10.1158%2F1078-0432.CCR-15-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lhE_yCHpeuiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>– <span class="NLM_lpage">14784</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768-14784&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0lhq6d8tCsqo4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26epage%3D14784%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2ea7e0wy1KPLRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGFR (d746-750/T790M/C797S) mutant-selective inhibitors via structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGFR+%28d746-750%2FT790M%2FC797S%29+mutant-selective+inhibitors+via+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0lhq6d8tCsqo4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGFR%2520%2528d746-750%252FT790M%252FC797S%2529%2520mutant-selective%2520inhibitors%2520via%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+dual+targeting+of+mutant+EGFR+with+an+allosteric+inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0lhGfMrrOahfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520dual%2520targeting%2520of%2520mutant%2520EGFR%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a new EGFR<sup>C797S</sup> mutant inhibitor with <i>in vivo</i> monodrug efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+new+EGFRC797S+mutant+inhibitor+with+in+vivo+monodrug+efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0lhGfMrrOahfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520new%2520EGFRC797S%2520mutant%2520inhibitor%2520with%2520in%2520vivo%2520monodrug%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span> <span> </span><span class="NLM_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR<sup>L858R/T790M</sup> mutant with improved pharmacokinetic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1016%2Fj.ejmech.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=28033579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=1107-1117&author=L.+Yuauthor=M.+H.+Huangauthor=T.+F.+Xuauthor=L.+J.+Tongauthor=X.+Y.+Yanauthor=Z.+Zhangauthor=Y.+Xuauthor=C.+H.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Y.+Lu&title=A+structure-guided+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+selective+inhibitors+of+EGFRL858R%2FT790M+mutant+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.ejmech.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties</span></div><div class="casAuthors">Yu, Lei; Huang, Minhao; Xu, Tianfeng; Tong, Linjiang; Yan, Xiao-e; Zhang, Zhang; Xu, Yong; Yun, Caihong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1107-1117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790M inhibitors with improved pharmacokinetic properties.  One of the most promising compd. 9s (N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide) potently suppressed EGFRL858R/T790M kinase and inhibited the proliferation of H1975 cells with IC50 values of 2.0 nM and 40 nM, resp.  The compd. dose-dependently induced redn. of the phosphorylation of EGFR and downstream activation of ERK in NCI-H1975 cells.  It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%.  Compd. 9s may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwni9j-NB9ZrVg90H21EOLACvtfcHk0lhGfMrrOahfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D&md5=0c4c9ab1f2e5eba185d817161c3e261b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%2BH.%26aulast%3DXu%26aufirst%3DT.%2BF.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DYan%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%2BY.%26atitle%3DA%2520structure-guided%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520selective%2520inhibitors%2520of%2520EGFRL858R%252FT790M%2520mutant%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117%26doi%3D10.1016%2Fj.ejmech.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance related EGFR T790M mutant</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1039/C5MD00208G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=10.1039%2FC5MD00208G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ygtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1693-1697&author=T.+F.+Xuauthor=T.+Pengauthor=X.+M.+Renauthor=L.+W.+Zhangauthor=L.+Yuauthor=J.+F.+Luoauthor=Z.+Zhangauthor=Z.+C.+Tuauthor=L.+J.+Tongauthor=Z.+R.+Huangauthor=X.+Y.+Luauthor=M.+Y.+Gengauthor=H.+Xieauthor=J.+Dingauthor=K.+Ding&title=C5-substituted+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+highly+specific+kinase+inhibitors+targeting+the+clinical+resistance+related+EGFR+T790M+mutant&doi=10.1039%2FC5MD00208G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant</span></div><div class="casAuthors">Xu, Tianfeng; Peng, Ting; Ren, Xiaomei; Zhang, Lianwen; Yu, Lei; Luo, Jinfeng; Zhang, Zhang; Tu, Zhengchao; Tong, Linjiang; Huang, Zhaoru; Lu, Xiaoyun; Geng, Meiyu; Xie, Hua; Ding, Jian; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1693-1697</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The development of specific kinase inhibitors has been a long-standing challenge in chem. biol. and drug discovery.  We have successfully discovered a series of C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific inhibitors against the clin. resistance-related EGFRT790M mutant.  One of the most promising compds., 9f, tightly binds to the EGFRT790M mutant and strongly inhibits its enzymic function with an IC50 value of 0.80 nM, and displays an extraordinary target specificity with S(35) and S(10) selectivity scores of 0.005 and 0.000, resp., in a kinase selectivity profiling study against 456 different kinases at 100 nM.  The compd. also selectively suppresses the proliferation of EGFRT790M mutated H1975 NSCLC cells with an IC50 value of 2.80 nM, but is significantly less toxic to cells with wild-type EGFR.  Compd. 9f may serve as a promising lead compd. for drug discovery overcoming the acquired resistance of NSCLC patients without adverse toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWwlWdk40U7Vg90H21EOLACvtfcHk0lidZL01yF8WqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ygtbvE&md5=f2ad8e6a8b5a45fd078c83f9c502c68e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC5MD00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00208G%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%2BF.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DL.%2BW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.%2BC.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DHuang%26aufirst%3DZ.%2BR.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DC5-substituted%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520highly%2520specific%2520kinase%2520inhibitors%2520targeting%2520the%2520clinical%2520resistance%2520related%2520EGFR%2520T790M%2520mutant%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1693%26epage%3D1697%26doi%3D10.1039%2FC5MD00208G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO','PDB','5ZTO'); return false;">PDB: 5ZTO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP','PDB','5GMP'); return false;">PDB: 5GMP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ','PDB','6JRJ'); return false;">PDB: 6JRJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK','PDB','6JRK'); return false;">PDB: 6JRK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i12"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00576">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_73525"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00576">10.1021/acs.jmedchem.9b00576</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic procedures, in vitro ELISA assay, cell proliferation inhibition assay, Western blot analysis, experimental data for the X-ray structures of <b>8c-A</b> and <b>8c-B</b>, computational study, solubility assay, metabolic stability, Caco-2 permeability assay, the kinase selectivity profiling study of <b>8r-B</b>, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <b>8a</b>–<b>r</b>, and HPLC purity analysis of <b>8a</b>–<b>r</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_002.csv">CSV</a>)</p></li><li><p class="inline">Characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_003.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_001.pdf">jm9b00576_si_001.pdf (8.53 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_002.csv">jm9b00576_si_002.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00576/suppl_file/jm9b00576_si_003.xlsx">jm9b00576_si_003.xlsx (44.9 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00576%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-15%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00576" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7a47a8743c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
